Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Glioblastoma 2Recurrence 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1Advanced Cancer 1Adenocarcinoma 1

Interventions

pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2satraplatin 1ixazomib 1X-Rays 1Valproic Acid 1Trastuzumab 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1Capecitabine 1Albumin-Bound Paclitaxel 1AH 111585 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancers × Crizotinib × Clear all
NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
178 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡